{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-functional/goals-outcome-measures/audit-criteria/","result":{"pageContext":{"chapter":{"id":"694c1d21-0d63-5dc6-bb90-b5acdbeb64ab","slug":"audit-criteria","fullItemName":"Audit criteria","depth":2,"htmlHeader":"<!-- begin field eb061059-8ac1-4edf-8044-459974fb2760 --><h2>Audit criteria</h2><!-- end field eb061059-8ac1-4edf-8044-459974fb2760 -->","summary":null,"htmlStringContent":"<!-- begin item 8cfcd609-efe9-4e48-a259-786cd1311022 --><!-- begin field 0a28dc20-bc45-4722-afa7-e987e58d8e8d --><p>The following National Institute for Health and Care Excellence (NICE) audit criteria are relevant for this CKS topic:</p><ul><li>Audit criterion 19. Eradication therapy is offered to people who test positive for <em>Helicobacter pylori </em>(<em>H. pylori</em>).</li><li>Audit criterion 20. If <em>H. pylori</em> has been excluded and symptoms persist, a low-dose PPI or an H<sub>2</sub>RA is offered for 4 weeks.</li><li>Audit criterion 21. If symptoms continue or recur after initial treatment, a PPI or H<sub>2</sub>RA is offered to be taken at the lowest dose possible to control symptoms.</li></ul><p><em>H. pylori</em> testing</p><ul><li>1. <em>H. pylori</em> is tested for using a carbon-13 urea breath test or a stool antigen test or laboratory-based serology.</li><li>2. Re-testing for <em>H. pylori</em> is performed using a carbon-13 urea breath test.</li><li>3. Office-based serological tests are not used.</li></ul><p>First-line <em>H. pylori</em> treatment</p><ul><li>4. People who test positive for <em>H. pylori</em> are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>amoxicillin and</li><li>either clarithromycin or metronidazole.</li></ul></li><li>5. People who are allergic to penicillin are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>clarithromycin and</li><li>metronidazole.</li></ul></li><li>6. People who are allergic to penicillin and who have had previous exposure to clarithromycin are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>bismuth and</li><li>metronidazole and</li><li>tetracycline.</li></ul></li></ul><p>Second-line <em>H. pylori</em> treatment</p><ul><li>7. People who still have symptoms after first-line eradication treatment are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>amoxicillin and</li><li>either clarithromycin or metronidazole (whichever was not used first-line).</li></ul></li><li>8. People who have had previous exposure to clarithromycin and metronidazole are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>amoxicillin and</li><li>a quinolone or tetracycline.</li></ul></li><li>9. People who are allergic to penicillin and have not had previous exposure to a quinolone are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>metronidazole and</li><li>levofloxacin.</li></ul></li><li>10. People who are allergic to penicillin and who have had previous exposure to a quinolone are offered:<ul><li>a PPI and</li><li>bismuth and</li><li>metronidazole and</li><li>tetracycline.</li></ul></li><li>11. If eradication of <em>H. pylori</em> is not successful with second-line treatment, advice is sought from a gastroenterologist.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">NICE, 2014</a>]</p><!-- end field 0a28dc20-bc45-4722-afa7-e987e58d8e8d --><!-- end item 8cfcd609-efe9-4e48-a259-786cd1311022 -->","topic":{"id":"5cc1cb73-764f-51c5-bc62-44f807111272","topicId":"36754870-050c-4543-8dfe-bee25a1d10bb","topicName":"Dyspepsia - proven functional","slug":"dyspepsia-proven-functional","lastRevised":"Last revised in October 2018","chapters":[{"id":"8b6fdb09-e6f3-5061-8539-ae2f57647698","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"63a6aa45-5022-5194-bebc-bd4481b831fe","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cdc4376-525a-5e58-8be2-dd0831642d02","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"257ffcf8-d6ac-58d1-b852-f9bb7329f249","slug":"changes","fullItemName":"Changes"},{"id":"d05055eb-ebd0-5056-b860-1ea85daeb311","slug":"update","fullItemName":"Update"}]},{"id":"b6f4608e-164d-578d-8142-8b175799683f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bf8575af-2f9b-5729-a628-5efb1ed0411d","slug":"goals","fullItemName":"Goals"},{"id":"761ef9c0-39a0-5dd7-9216-2dc7963b0a6a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"694c1d21-0d63-5dc6-bb90-b5acdbeb64ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9244dd4a-0551-5975-b909-6d728dfadcdd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9029a91f-3843-5e59-8544-cb7adfa2c457","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19b1713f-a518-57e7-a0c1-cdb48d0b4a0d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e265526e-adb9-5805-aedd-2e2bc77bb54c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"93b80ba3-9d73-5fc5-8b0e-7a57de8d6107","slug":"definition","fullItemName":"Definition"},{"id":"8f596c75-9a83-5d33-8b9a-4d18a9e24e2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0a9f461a-38b9-56d1-8511-e41e822e0e8a","slug":"complications","fullItemName":"Complications"},{"id":"e7524b44-b1cf-50d9-806d-bd52695ec307","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a156deba-ce54-58e0-8984-13e20203cd70","fullItemName":"Management","slug":"management","subChapters":[{"id":"ff03390b-be65-558d-83cf-6808e0b84339","slug":"management-of-functional-dyspepsia","fullItemName":"Scenario: Management of functional dyspepsia"}]},{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c3d76d92-046e-5ac3-84fa-c59eff3cd774","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"8ad244d5-29e6-5577-8efb-eae73fd2faad","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"29d86046-683d-5047-a344-9b0961e8916a","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"891aafa8-13c0-5175-b0ac-580bd4cbe1b8","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"c11610d4-e4be-5dbb-baf5-5414f7bea599","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"a8c93904-08fc-57a4-b238-068ab96b5615","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"6075addb-8b4a-5e26-9d73-a9cd48dd70f3","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"348b1111-2664-52e1-9fd6-2d26abd69bcb","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"2d629b23-aa42-5503-980b-2c202de4c387","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4be75458-608e-5c04-9441-7001ced7fc6d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6ad0185f-1607-5a33-9e94-892b09578c17","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6489fce3-cac9-583f-a217-70ba5562de71","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e29927f4-a004-5126-a503-f1045ce72a28","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ca579371-2f3e-59ad-887e-7215f885a62a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"de65b79c-b356-54be-a611-9a871e60c85e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"43271e4f-f094-520d-bd20-f6582fc6ba97","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b6f4608e-164d-578d-8142-8b175799683f","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}